There was no difference in the proportion of CD4+ cells in PBL between MS patients and HD (42.14% ± 13.14% vs. 41.26% ± 6.19%, p = 0.339) though the variation within MS patients was greater than in HD (Fig. 1Bd). The gene discussed is CD4; the disease is myeloid sarcoma.